weight loss drug novo nordisk

Novo Nordisk, drug Wegovy

Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce treatments using Zealand's experimental petrelintide injectable.

CNBC on MSN · 4d

Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

USA TODAY on MSN · 8d

Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight-loss drug Wegovy.

Novo Nordisk Skeptic Finally Upgrades Stock

The Motley Fool on MSN · 1d

Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics ( VKTX 10.22%) and Roche Holdings ( RHHBY 3.62%), up 11.3% and 4%, respectively, through 10:05 a.m. ET today, are behind it.

Bloomberg L.P. · 1d

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.

Business Insider · 1d

Novo Nordisk upgraded to Buy from Hold at Kepler Cheuvreux

Kepler Cheuvreux upgraded Novo Nordisk (NVO) to Buy from Hold with a price target of DKK 630, down from DKK 715. The firm views the company’s

4don MSN

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

MedCity News4d

Novo Nordisk’s Next-Gen Obesity Drug Disappoints Again With Lower Than Expected Weight Loss

A next-generation Novo Nordisk metabolic disorder drug led to statistically significant weight loss in a pivotal test in participants with obesity and type 2 diabetes, results it says ...

Compound versions of some weight loss drugs to be restricted

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Novo Nordisk, drug Wegovy

Novo Nordisk Skeptic Finally Upgrades Stock

Trending now